Related Experiment Videos
Sequential polychemotherapy in exocrine pancreatic cancer
R Klapdor1, M Bahlo, A Babinski
1Medical Department, Jerusalem Hospital, ZeTDT GmbH, Hamburg, Germany.
Anticancer Research
|June 25, 2003
Summary
Efficacy-orientated sequential polychemotherapy (EOSP) shows promise for improving survival in exocrine pancreatic cancer patients. This palliative chemotherapy approach demonstrated notable treatment responses and prolonged survival, particularly in metastatic cases.
Area of Science:
- Oncology
- Gastroenterology
Background:
- Exocrine pancreatic cancer has a poor prognosis.
- Palliative chemotherapy is a key treatment modality.
Purpose of the Study:
- To evaluate the efficacy of efficacy-orientated sequential polychemotherapy (EOSP) in exocrine pancreatic cancer patients.
- To assess the impact of EOSP on patient survival rates.
Main Methods:
- Retrospective analysis of 162 exocrine pancreatic cancer patients treated between 1998 and 2001.
- Assessment of treatment response including stable disease (SD), minimal response (MR), partial response (PR), and complete response (CR).
Main Results:
- EOSP induced more than one effective treatment in approximately 40% of patients.
- Overall 1-year survival was 56% and 2-year survival was 16%.
- For metastatic disease (M1), 1-year survival was 45% and 2-year survival was 12%.
Conclusions:
- Sequential polychemotherapy appears to prolong survival in exocrine pancreatic cancer patients.
- EOSP shows potential benefits, especially in metastatic cases, warranting further investigation.
- Results encourage more active use of palliative chemotherapy and re-evaluation of trial designs.